Infinity and MedImmune Report Generic Name Approval for Cancer Drug
Posted on: Wednesday, 6 February 2008, 09:01 CST
Infinity Pharmaceuticals and MedImmune have said that the US Adopted Names Council, in consultation with the World Health Organization International Nonproprietary Names Expert Committee has approved the use of the nonproprietary or generic name retaspimycin for the companies' heat shock protein 90 inhibitor, IPI-504.
Retaspimycin hydrochloride is currently being evaluated in clinical trials for the potential treatment of a variety of solid tumor cancers, including gastrointestinal stromal tumors, non-small cell lung cancer, and hormone resistant prostate cancer.
Source: Datamonitor
Related Articles
Rating: 1.7 / 5 (3 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds